0.2700GBp+1.89%Mkt Cap: 1.79M GBpP/E: —Last update: 2026-05-13
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II tri…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
P/B0.22
P/S29.85
EV/EBITDA0.12
EV/Revenue-4.08
EPS (TTM)-0.01
EPS (Forward)-1.86
Cash Flow & Leverage
FCF Yield-59.71%
FCF Margin-2147.28%
Operating CF-1.58M GBp
CapEx (TTM)38.16K GBp
Net Debt/EBITDA0.29
Net Debt-512.13K GBp
Technical
SMA 500.2924 (-7.7%)
SMA 2000.3943 (-31.5%)
Beta-0.56
S&P 52W Chg24.23%
Avg Vol (30d)2.80M
Avg Vol (10d)11.80M
Technical Indicators
RSI (14)32.4
MACD-0.0105
MACD Signal-0.0097
MACD Hist.-0.0008
BB Upper0.3145 GBp
BB Middle0.2835 GBp
BB Lower0.2525 GBp
BB Width21.85%
ATR (14)0.0259 GBp
Vol Ratio (20d)13.54x
52W Range
0.22008% of range0.8750
52W High0.8750 GBp
52W Low0.2200 GBp
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin-3848.71%
Oper. Margin-4053.35%
ROE-44.37%
ROA-44.95%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.00
Current Ratio9.66
Quick Ratio8.87
Book Value/Sh0.0090 GBp
Cash/Share0.0010 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:125
Split DateApr 6, 2020
Ownership
Shares Out.742.80M
Float335.43M
Insiders11.68%
Institutions0.00%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap1.79M GBp
Enterprise Value-203.32K GBp
Revenue (TTM)49.77K GBp
Gross Profit49.77K GBp
Net Income (TTM)-1.92M GBp
Revenue/Share0.0000 GBp
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees14
Last Price0.2700 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINLU1598690169